Corvus Pharmaceuticals (CRVS) Receivables - Other (2021 - 2024)

Corvus Pharmaceuticals (CRVS) posted quarterly Receivables - Other of $70000.0 for Q3 2024, up 100.0% quarter-over-quarter from $35000.0 in Q2 2024.

Corvus Pharmaceuticals (CRVS) Receivables - Other (2021 - 2024) Analysis & Trends

Corvus Pharmaceuticals' Receivables - Other history runs 4 years deep, the most recent figure standing at $70000.0 for Q3 2024.

In Q3 2024, Receivables - Other changed N/A year-over-year to $70000.0; the TTM figure through Sep 2024 stood at $70000.0 (changed N/A YoY), while the FY2023 annual figure was $26000.0, down 95.58% from the prior year.
Receivables - Other for Q3 2024 stood at $70000.0, up from $35000.0 in the prior quarter.
The five-year high for Receivables - Other was $588000.0 in Q4 2022, with the low at $26000.0 in Q4 2023.
The 4-year median for Receivables - Other is $373000.0 (2022), against an average of $291454.5.
The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 82.25% in 2022, then sank 95.58% in 2023.
Corvus Pharmaceuticals' Receivables - Other stood at $507000.0 in 2021, then increased by 15.98% to $588000.0 in 2022, then tumbled by 95.58% to $26000.0 in 2023, then jumped by 169.23% to $70000.0 in 2024.
Business Quant data shows CRVS's Receivables - Other at $70000.0 in Q3 2024, $35000.0 in Q2 2024, and $26000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Corvus Pharmaceuticals	1.25 Bn	1.04 Bn	-

Download Data